Tag Archive for: Telavant Holdings

TLA1 mode of action. In fibrosis, the compound's binding to its receptor induces TGF-beta and IL6 release. © Prometheus Biosciences/MSD

Analysts describe as sporting the €7.1bn for Roche AG’s acquisition of Roivant subsidiary Telavant Holdings.